Abstract: Improved delivery and absorption of erythromycin in warm-blooded animals is achieved by administering thereto a non-toxic pharmaceutical effervescent enteric-coated tablet comprising:(a) an antibiotic effective amount of a non-toxic pharmaceutically acceptable soluble form of erythromycin;(b) a non-toxic pharmaceutically acceptable inert diluent; and(c) a non-toxic pharmaceutically acceptable effervescent couple acid and base; and(d) a non-toxic pharmaceutically acceptable enteric coating maintained over the tableted mixture of (a), (b), and (c) above.The subject composition is extremely useful in the treatment of bacterial infections in warm-blooded animals, particularly in the mitigation and treatment of upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity.

Abstract: Therapeutic and undegraded levels of digoxin in warm-blooded animals are achieved by orally admininstering thereto, a non-toxic pharmaceutical enteric-coated tablet comprising:(a) A cardiotonic effective amount of digoxin;(b) a non-toxic pharmaceutically acceptable inert diluent, and(c) a standard non-toxic pharmaceutically acceptable enteric coating.This composition is extremely useful in the treatment of cardiac insufficiency in warm-blooded animals. When administered to warm-blooded animals (e.g., humans), superior therapeutic and undegraded blood levels of digoxin are observed over that normally observed with conventional solid dosage formulations for oral administration.

Abstract: The intraocular pressure of a warm-blooded animal is substantially reduced by administering topically to the eye thereof, a therapeutically effective amount of a compound of the formula: ##SPC1##Or a pharmaceutically acceptable acid addition salt thereof.